WELCOME TO THE SOUND OF SCIENCE PODCAST PAGE!
This series covers several topics regarding the progress made in the HIV treatment landscape over the last couple of years, best practices in HIV care, as well as the importance of good HCP- People living with HIV (PLHIV) dialogue and involvement in shared decision-making.
ROF. ESTEBAN MARTINEZ, SENIOR CONSULTANT IN INFECTIOUS DISEASES AT HOSPITAL CLÍNIC OF BARCELONA, SPAIN AND DR BRYN JONES, ViiV HEALTHCARE.
Episode 5 PASO DOBLE data - 48-week data presented at AIDS 2024
In this episode, Professor Esteban Martínez, the principal investigator of the PASO DOBLE trial, will discuss the main results of the largest head-to-head study of Dovato vs. BIC/FTC/TAF
PM-GBL-DLL-AUDI-240001 Sep 2024
Switching to BIC/FTC/TAF led to a statistically significant greater weight gain vs. switching to DOVATO1 Treatment difference= 0.92 kg (95% CI: 0.17, 1.66; p=0.016)
- Martinez E et al. Presented at AIDS. 22 - 26 July 2024. Munich, Germany.
- DOVATO. Summary of Product Characteristics. April 2024.
PROF. CHLOE ORKIN AND DR PERRY MOHAMMED, HEAD OF MEDICAL AFFAIRS, EUROPE, ViiV HEALTHCARE.
Episode 4 Real – World Evidence with Long Acting HIV Therapies
This episode examines real-world data for cabotegravir▼+ rilpivirine▼and it's impact on clinical practice.
PM-GBL-HVX-AUDI-230003 Dec 2023
- Sension et al. IDWeek 2023. Poster 1608.
- Deschanvres et al. EACS 2023. MeP.T2.01
- Jongen et al. EACS 2023. Oral presentation PS8.O3;
- Ring et al. EACS 2023. eP.A.056
- Ramirez et al. EACS 2023. Oral presentation and Abstract
- Sinclair et al. IDWeek 2023.. Poster 1607
- Seang et al. EACS 2023. Poster eP.A.074
- Psomas et al. EACS 2023. Poster eP.A.016
- Vannappagari V, et al. EACS 2-23 . Poster eP.A.039
- Fernández-Hinojal et al. EACS 2023. Poster eP.A.026;
- Bana et al. EACS 2023. Poster eP.A.047
- Ferré et al. EACS 2023. Poster eP.A.042
- Nasser et al. EACS 2023
PROF. MARIE-ANGÉLIQUE DE SCHEERDER, INTERNAL MEDICINE AND INFECTIOUS DISEASE SPECIALIST, GHENT UNIVERSITY HOSPITAL AND DR BRYN JONES, ViiV HEALTHCARE.
Episode 3 RUMBA data– Importance of metabolic endpoints for HIV
This podcast highlights the key data, results, and conclusions that can be drawn from the RUMBA clinical trial results, specifically linking to how/why metabolic outcomes are important for for people living with HIV
CATARINA ESTEVES SANTOS, REGISTERED NURSE AND MENTAL HEALTH SPECIALIST NURSE HIV UNIT, CASCAIS HOSPITAL AND "JAMES" (LIVING WITH HIV)
Episode 2 Impact of Stigma and Fear of Disclosure for people Living with HIV (PLHIV)
In this episode we will be discussing HIV stigma and looking at some of the key unmet needs for people Living with HIV.
PROF. CHLOE ORKIN, LEAD FOR HIV RESEARCH AT BARTS HEALTH NHS TRUST, LONDON, UK AND DR PERRY MOHAMMED, HEAD OF MEDICAL AFFAIRS, EUROPE, ViiV HEALTHCARE.
Episode 1 SOLAR Data – What does this mean for people living with HIV (PLHIV)?
This episode highlights the key data and conclusions that can be drawn from the SOLAR results that were presented during the 30th Conference on Retroviruses and Opportunistic Infections (CROI), held in Seattle, Washington.
- Ramgopal MN, et al. Lancet HIV 2023;10:e566–e577;ePub ahead of print (and suppl. appendix)
- Chounta V, et al. IAS 2023. Poster TUPEB06
PM-GB-CBR-AUDI-230001 Oct 2023
PM-GBL-HVX-WCNT-230023 March 2024
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
